NVO - Senate committee wants Novo Nordisk exec to testify on high Ozempic Wegovy prices
2024-06-11 11:52:50 ET
More on Novo Nordisk
- Novo Nordisk: The Market Is Right, Don't Fight Against It
- Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study
- Novo Nordisk: Considerable Growth Beyond Ozempic
-
Novo Nordisk's Ozempic cuts mortality risk in kidney disease